Milestone Pharmaceuticals starts Phase 3 AFib-RVR trial for etripamil

August 21, 2026 8:00 AM

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) announced Aug. 21, 2026, that the first patient has been enrolled in the ReVeRA-301 Phase ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found